Michael R. Kurman

966 total citations
56 papers, 717 citations indexed

About

Michael R. Kurman is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael R. Kurman has authored 56 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 17 papers in Molecular Biology and 13 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael R. Kurman's work include Cancer, Hypoxia, and Metabolism (7 papers), Prostate Cancer Treatment and Research (6 papers) and T-cell and Retrovirus Studies (5 papers). Michael R. Kurman is often cited by papers focused on Cancer, Hypoxia, and Metabolism (7 papers), Prostate Cancer Treatment and Research (6 papers) and T-cell and Retrovirus Studies (5 papers). Michael R. Kurman collaborates with scholars based in United States, United Kingdom and Japan. Michael R. Kurman's co-authors include Karen M. Dwyer, Pramoda Challagundla, Youn H. Kim, Jeffrey L. Jorgensen, Li Liu, Francine M. Foss, Xiaoping Zhang, Madeleine Duvic, Lauren Pinter‐Brown and Lubomir Sokol and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Michael R. Kurman

54 papers receiving 703 citations

Peers

Countries citing papers authored by Michael R. Kurman

Since Specialization

Citations

This map shows the geographic impact of Michael R. Kurman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. Kurman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. Kurman more than expected).

Fields of papers citing papers by Michael R. Kurman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. Kurman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. Kurman. The network helps show where Michael R. Kurman may publish in the future.

Co-authorship network of co-authors of Michael R. Kurman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. Kurman. A scholar is included among the top collaborators of Michael R. Kurman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. Kurman. Michael R. Kurman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I, first-in-human trial of KO-947, an ERK1/2 inhibitor, in patients with advanced solid tumors 2025 ·ESMO Open ·Alison M. Schram, (unknown), Alex A. Adjei, Anthony J. Olszanski, María Vieito, Jasmine H. Francis, Michael R. Kurman, (unknown), Birgitta Tomkinson, (unknown)	0
2	A phase 1 study of the irreversible FLT3 inhibitor FF-10101 in relapsed or refractory acute myeloid leukemia 2024 ·Blood Advances ·Mark J. Levis, Alexander E. Perl, Gary J. Schiller, Amir T. Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Trivikram Rajkhowa, Makoto Ando, (unknown), Ruth Ann Subach, (unknown), Timothy Madden, Mary Johansen, K.Y. Cheung, Michael R. Kurman, Catherine C. Smith	9
3	A Phase 1, Open-Label, Multicenter Study of Treatment with ACE1831, Comprised of Allogeneic Gamma Delta T Cells Conjugated to an Anti-CD-20 Antibody, in Patients (Pts) with B-Cell Relapsed/Refractory Non-Hodgkin's Lymphoma (R/R NHL) 2024 ·Blood ·Don A. Stevens, Jason T. Romancik, Rushang D. Patel, (unknown), Janet Pan, (unknown), (unknown), Sai-Wen Tang, (unknown), Jerry Liu, Michael R. Kurman	0
4	Abstract CT172: A phase 1, open-label, dose-escalation study of PRT1419, a selective induced myeloid leukemia cell differentiation protein (MCL-1) inhibitor, in patients (pts) with advanced/metastatic solid tumors 2023 ·Cancer Research ·Gerald S. Falchook, Manish R. Patel, Meredith McKean, Alexander Philipovskiy, Rachel Chiaverelli, William Sun, Michael J. Fossler, William Novotny, Michael R. Kurman, Sarah Rowe, Deborah Hunter, Mohammed Milhem	6
5	SAFETY AND TOLERABILITY OF CAEL-101, AN ANTI-AMYLOID MONOCLONAL ANTIBODY, IN COMBINATION WITH PLASMA CELL DYSCRASIA THERAPY IN PATIENTS WITH LIGHT-CHAIN AMYLOIDOSIS: RESULTS FROM A PHASE 2 STUDY 2022 ·Journal of the American College of Cardiology ·Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, (unknown), Michael R. Kurman, (unknown), (unknown), Mark T. Harnett, (unknown), Candida Cristina Quarta, (unknown), (unknown), Michael Spector, Susan B. Sobolov	3
6	1006P ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors 2021 ·Annals of Oncology ·Sarina A. Piha‐Paul, Devalingam Mahalingam, (unknown), (unknown), (unknown), (unknown), Michael R. Kurman, (unknown), (unknown), (unknown), (unknown), (unknown), Sheng‐Hsuan Chien	2
7	797 Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel) 2020 ·SHILAP Revista de lepidopterología ·Nikhil I. Khushalani, Andrew S. Brohl, Joseph Markowitz, Lyudmila Bazhenova, Gregory A. Daniels, (unknown), Siqing Fu, (unknown), Michael R. Kurman, (unknown), Gloria Lee, Zeynep Eroglu	4
8	The AIM-HN and SEQ-HN study: A pivotal study evaluating the efficacy of tipifarnib in patients with head and neck squamous cell carcinoma (HNSCC) with hras mutations (AIM-HN) and the impact of hras mutations on response to first line systemic therapies for HNSCC (SEQ-HN). 2020 ·Journal of Clinical Oncology ·Robert I. Haddad, Kevin J. Harrington, Lisa Licitra, Amanda Psyrri, Nabil F. Saba, Natasa Rajicic, Binaifer Balsara, Michael R. Kurman, Catherine Scholz, Antonio Gualberto, Alan L. Ho	1
9	Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma 2019 ·Repositorio Académico USMP ·Adrienne A. Phillips, Paul Fields, Olivier Hermine, Juan Carlos Ramos, Brady Beltrán, Juliana Pereira, (unknown), Tatyana Feldman, Graham P. Taylor, Ahmed Sawas, Jeffrey S. Humphrey, Michael R. Kurman, Junji Moriya, Karen M. Dwyer, Mollie Leoni, Kevin C. Conlon, Lucy Cook, (unknown), Steven M. Horwitz	5
10	Mogamulizumab versus investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma 2018 ·Haematologica ·Adrienne A. Phillips, Paul Fields, Olivier Hermine, Juan Carlos Ramos, Brady Beltrán, Juliana Pereira, (unknown), Tatyana Feldman, Graham P. Taylor, Ahmed Sawas, Jeffrey S. Humphrey, Michael R. Kurman, Junji Moriya, Karen M. Dwyer, Mollie Leoni, Kevin C. Conlon, Lucy Cook, (unknown), Steven M. Horwitz	48
11	A Phase 1b/2a Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Nano-Genistein and Chemoradiotherapy for Non-Small Cell Lung Cancer 2018 ·International Journal of Radiation OncologyBiologyPhysics ·Michael D. Kaytor, Steven Brown, (unknown), Michael R. Kurman, (unknown), (unknown), (unknown), (unknown), Sreedevi K. Menon, Jonathan R. Thompson, (unknown), (unknown), Elizabeth Gore, Benjamin Movsas	1
12	A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma 2017 ·British Journal of Cancer ·Jamie Cavenagh, Heather Oakervee, (unknown), Faith E. Davies, Mecide Gharibo, Neil Rabin, Michael R. Kurman, (unknown), Norihiko Shiraishi, Daisuke Nakashima, Shiro Akinaga, Kwee Yong	42
13	Cardiovascular safety profile of VT-464 in patients (pts) with castrate-resistant prostate cancer (CRPC). 2016 ·Journal of Clinical Oncology ·Michael R. Kurman, Philip T. Sager, Marc S. Rudoltz, Joel R. Eisner, Daniel B. Goodman, Eugene R. Heyman, (unknown), C. Cooper Bell, William R. Moore	1
14	BTH1677 in combination with cetuximab with and without irinotecan in patients with advanced metastatic colorectal cancer 2016 ·Gerardo Cornelio, María Tamayo, (unknown), (unknown), (unknown), Michele Gargano, Michael R. Kurman, Richard M. Walsh, Martin Béliveau, Jean‐Francois Marier, Myra L. Patchen	4
15	Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours 2016 ·British Journal of Cancer ·Devalingam Mahalingam, George Wilding, Samuel R. Denmeade, (unknown), David Cosgrove, Jeremy Cetnar, Nilofer S. Azad, Justine Y. Bruce, Michael R. Kurman, Victoria Allgood, Michael A. Carducci	123
16	A phase I, dose-escalation, multicenter study of ACT-PFK-158, 2HCl in patients with advanced solid malignancies explores a first-in-human inhibitor of glycolysis. 2015 ·Journal of Clinical Oncology ·Rebecca Redman, Paula R. Pohlmann, Michael R. Kurman, Gilles Tapolsky, Jason Chesney	15
17	Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies 2014 ·Blood ·David S. Siegel, Andrew McDonald, Nicolás Novitzky, William Bensinger, Michael Craig, Frits van Rhee, Martin Gutierrez, Edward N. Libby, John E. Thompson, Alice Bexon, (unknown), Catherine Taylor, (unknown), Leslie J. Browne, Michael R. Kurman, John A. Lust	1
18	Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy 2008 ·Annals of Oncology ·Dwight E. Heron, Adam Brufsky, Sushil Beriwal, Michael R. Kurman	15
19	A trial of IRX-2 in patients with squamous cell carcinomas of the head and neck 2003 ·International Immunopharmacology ·John W. Hadden, Emma Verástegui, José Luís Barrera, Michael R. Kurman, Abelardo Meneses, Juan W Zinser, Horacio Astudillo‐de la Vega, Elba M. Hadden	28
20	Recent Clinical Trials with Levamisole 1993 ·Annals of the New York Academy of Sciences ·Michael R. Kurman	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact